THC Farmaceuticals

THC Farmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of THC Farmaceuticals (CBDG) as of Oct 15, 2026 is -4,243.68 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 74.46 % — a change of -5,799.16% (lower).

FCF Conversion

-4,243.68 %

YoY

-5,799.16%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of THC Farmaceuticals is 2023 -4,243.68 % . FCF Conversion Rate (FCF/EBITDA) of THC Farmaceuticals was 2022 74.46 % . It decreases by -5,799.16% lower compared to the previous year.

The THC Farmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
124.74 USD
Jan 1, 2017
95.89 USD
Jan 1, 2018
60.02 USD
Jan 1, 2019
26.92 USD
Jan 1, 2020
3.65 USD
Jan 1, 2021
139.69 USD
Jan 1, 2022
74.46 USD
Jan 1, 2023
-4,243.68 USD
The THC Farmaceuticals FCF Conversion history
YEARFCF ConversionYoY
-4,243.68 %-5,799.16%
74.46 %-46.70%
139.69 %+3,727.58%
3.65 %-86.45%
26.92 %-55.14%
60.02 %-37.41%
95.89 %-23.13%
124.74 %+102.61%
61.56 %—
Access this data via the Eulerpool API

THC Farmaceuticals Stock analysis

What does THC Farmaceuticals do? THC Farmaceuticals Inc. is a Canadian company specializing in the production of medical cannabis products. It was founded in 2015 and is headquartered in Langley, British Columbia. The company is a registered publicly traded company, listed on the Canadian Securities Exchange (CSE) under the symbol THC and also traded on the OTC market in the USA. The company was founded by two friends, John Miller and Erik Shaw, who were both involved in agriculture and had a mutual interest in medical cannabis. They recognized the potential of the plant and began growing their own strains. Over time, they developed unique cultivars that were rich in cannabinoids and had a high therapeutic effect. Their approach has always been to produce medical cannabis of the highest quality and purity. In 2017, THC Farmaceuticals obtained the license to produce medical cannabis and started bringing its products to the market. The company has since grown in Canada and the USA and expanded its presence in the international market. THC Farmaceuticals' business model focuses on the production of medical cannabis. The company cultivates its own plants and extracts cannabinoids. The extraction of cannabinoids, such as THC and CBD, is an essential step in the production of medical cannabis. These components are offered by THC Farmaceuticals in different concentrations to meet the needs of customers. In addition, the company focuses on producing products for the medical and recreational sectors. The offered products include cannabis concentrates, oils, capsules, inhalation devices, and edible products such as candies and chocolates. THC Farmaceuticals stands out for its wide range of products to meet the needs of consumers and patients with different requirements. THC Farmaceuticals focuses on two main areas: 1. Medical sector: THC Farmaceuticals offers a wide range of cannabis products for patients with various conditions. The company works closely with doctors and healthcare professionals to ensure its products meet the needs of patients. There are numerous studies that demonstrate the efficacy of medical cannabis in treating various conditions, such as pain, epilepsy, cancer, and multiple sclerosis. 2. Recreational sector: THC Farmaceuticals also offers a wide range of cannabis products for the recreational sector. These products are intended for adults who consume cannabis for pleasure or relaxation. There is a growing demand for recreational cannabis products in Canada and the USA, especially after the legalization of cannabis in some states. THC Farmaceuticals offers a wide range of cannabis products suitable for the medical and recreational sectors. Some of the products offered by the company include: 1. Cannabis concentrates: These are highly concentrated forms of cannabis with a high therapeutic effect. THC Farmaceuticals offers a wide selection of concentrate forms, including oils, extracts, and isolates. 2. Edible products: THC Farmaceuticals offers a wide range of edible cannabis products, such as chocolates and candies. These products are a popular way to consume cannabis without smoking or inhaling it. 3. Inhalation devices: THC Farmaceuticals offers a wide range of inhalation devices, such as vaporizers and e-cigarettes. These devices provide an effective and gentle way to inhale cannabis. In conclusion, THC Farmaceuticals is a rising company specializing in the production of medical cannabis products. The company offers a wide range of products suitable for the medical and recreational sectors. With its extensive range and commitment to quality and purity, THC Farmaceuticals has become a major player in the cannabis market. THC Farmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about THC Farmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of THC Farmaceuticals is -4,243.68 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of THC Farmaceuticals changed from 74.46 % to -4,243.68 %, representing a -5,799.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) THC Farmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s THC Farmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — THC Farmaceuticals

All Key Metrics — THC Farmaceuticals